Study of Real-world Evidence With SGLT2i (Dapagliflozin) and DPP4i (Sitagliptin) in Type 2 Diabetes Patients in Spain

NCT04149067 · clinicaltrials.gov ↗

COMPLETED

Status

1080

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Dapagliflozin
DRUG: Sitagliptin

Sponsor

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Collaborators

[object Object]